ClinicalTrials.gg
CompletedNCT00922272Updated Jun 9, 2021Results posted

Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms

A Phase 2 interventional study of SPD489 (lisdexamfetamine dimesylate) and Placebo matching SPD489 (lisdexamfetamine dimesylate) in Schizophrenia and Predominant Negative Symptoms, sponsored by Shire. Completed at 27 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Schizophrenia by Takeda — none open to participants now, none under way, none of them phase 3. Schizophrenia · Takeda.

Enrollment
2nd of 11
92 · median 20
Started
2009
the only one that year
Phase 2
2 of 11
none open now
Registered
1st of 11
by date

Among the 11 studies in Schizophrenia by Takeda, this one is the 2nd largest by enrollment, is the only one that started in 2009, is one of 2 in phase 2, and was the 1st registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 11 studies in Schizophrenia by Takeda is open now. The open studies under Schizophrenia, anywhere →

Where they have run

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Schizophrenia by Takeda as a file.
02

Study summary

To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as measured by the Scale for the Assessment of Negative Symptoms (SANS).

03

Conditions studied

  • Schizophrenia and Predominant Negative Symptoms

Browse trials for

Keywords

  • Schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-55
  • Clinically stable Schizophrenia and predominant negative symptoms
  • Taking a stable dose of antipsychotic medication

Exclusion criteria

Exclusion Criteria:

  • Clinically notable positive symptoms defined by PANSS
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    SPD489 (Lisdexamfetamine dimesylate)

    Drug: SPD489 (lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo matching SPD489 (lisdexamfetamine dimesylate)

Interventions

  • oral, 20, 30, 40, 50, 60, or 70 mg once daily

    Also known as: Vyvanse

  • DrugPlacebo matching SPD489 (lisdexamfetamine dimesylate)

    oral, once daily

06

What researchers measure

Primary outcomes

  1. Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  2. Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)

    The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

Secondary outcomes

  1. Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase

    Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Week 10 Open-label Phase

  2. Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase

    Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Week 4 Double-blind Phase

  3. Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase

    The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  4. Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase

    The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

  5. Change From Open-label Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at Week 10 Open-label Phase, LOCF

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  6. Change From Double-blind Randomization Baseline in PANSS Scores at Week 4 Double-blind Phase, TOCF

    The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

  7. Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Open-label Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Open-label Baseline

  8. Percent of Participants With CGI-S at Week 10 Open-label Phase

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Week 10 Open-label Phase

  9. Percent of Participants With CGI-S at Double-blind Randomization Baseline

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Double-blind Randomization Baseline

  10. Percent of Participants With CGI-S at Week 4 Double-blind Phase

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Week 4 Double-blind Phase

  11. Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase

    CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Open-label Phase Week 10

  12. Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase

    CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Double-blind Phase Week 4

  13. Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase

    BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

    Time frame: Open-label Baseline and week 10 Open-label Phase

  14. Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase

    BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

    Time frame: Double-blind Randomization Baseline and Week 4

  15. Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase

    LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

    Time frame: Open-label Baseline and week 10 Open-label Phase

  16. Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase

    LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

    Time frame: Double-blind Randomization Baseline and Week 4

  17. Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase

    HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

    Time frame: Open-label Baseline and Week 10

  18. Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase

    HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

    Time frame: Double-blind Randomization Baseline and week 4 Double-blind Phase

  19. Change From Open-label Baseline in University of California Performance-Based Skills Assessment, Brief Version (UPSA-B) Scores at Week 10 Open-label Phase, LOCF

    UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

    Time frame: Open-label Baseline and week 10 Open-label Phase

  20. Change From Double-blind Randomization Baseline in UPSA-B Scores at Week 4 Double-blind Phase

    UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

  21. Change From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  22. Change From Double-blind Randomization Baseline in BRIEF-A T-Scores at Week 4 Double-blind Phase

    BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

  23. Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  24. Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase

    SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

  25. Change From Open-label Baseline in Barnes Akathisia Scale (BAS) Scores at Week 10 Open-label Phase

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Open-label Baseline and week 10 Open-label Phase

  26. Change From Open-label Baseline in BAS Scores at Week 4 of Double-blind Phase

    BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

  27. Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  28. Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase

    ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

    Time frame: Double-blind Randomization Baseline and Week 4 Double-blind Phase

  29. Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase

    PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  30. Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase

    PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

    Time frame: Open-label Baseline and Week 4 Double-blind Phase

  31. Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Open-label Baseline and Week 10 Open-label Phase

  32. Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase

    CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

    Time frame: Open-label Baseline and Week 4 of Double-blind Phase

07

Results

Posted Feb 20, 2012

Participant flow

Open-label Phase
Participant flow — Open-label Phase
MilestoneSPD489Placebo
Started920
Completed690
Not completed230
Withdrew: Adverse event50
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject110
Withdrew: Failure to meet randomization criteria10
Withdrew: Withdrawal criteria met50
Double-blind Phase
Participant flow — Double-blind Phase
MilestoneSPD489Placebo
Started3435
Completed2729
Not completed76
Withdrew: Adverse event11
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up21
Withdrew: Withdrawal criteria met11
Withdrew: Noncompliance11
Withdrew: Positive urine drug screen11

Outcome measures

PrimaryChange From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)
Units on a scaleSPD489 (Open-label Phase)
Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried Forward (LOCF)-12.9 ± 10.04
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
SecondaryPercent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase

Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Week 10 Open-label Phase
Reported as:
Number · Percent of participants
Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase
Percent of participantsSPD489 (Open-label Phase)
Percent of Participants In Open-label Phase Who Were SANS-18 Responders at Week 10 Open-label Phase52.9
PrimaryChange From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)

The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Least squares mean · Units on a scale
Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Double-blind Randomization Baseline in SANS-18 Total Score at Week 4 Double-blind Phase, Termination Observation Carried Forward (TOCF)4.5 ± 2.142.2 ± 1.85
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.4182 · Mean difference (final values): 2.3 · 95% CI -3.4 to 8.1
SecondaryPercent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase

Response is defined as reduction in total SANS score of greater than or equal to 20%. The SANS was modified by eliminating the global and attention items; the score of the remaining non-global items is referred to as the SANS-18 total score. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Week 4 Double-blind Phase
Reported as:
Number · Percent of participants
Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase
Percent of participantsSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Percent of Participants In Double-blind Phase Who Maintained SANS-18 Response at Week 4 Double-blind Phase71.482.4
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · Fisher Exact · p = 0.6705
SecondaryChange From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase

The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in SANS Global Scores at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Affective Flattening-0.9 ± 0.80
Alogia-0.9 ± 0.65
Avolition-Apathy-0.5 ± 0.81
Anhedonia-Asociality-0.7 ± 0.77
Attention-0.7 ± 0.80
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
SecondaryChange From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase

The SANS assesses 5 symptom complexes to rate the negative symptoms of subjects. Each of the 18-items is scored on a scale from 0 (not at all) to 5 (severe) with a total scoring range of 0 to 90. Higher scores indicate more impairment.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Least squares mean · Units on a scale
Change From Double-blind Randomization Baseline in SANS Global Scores at Week 4 Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Affective Flattening0.2 ± 0.170.2 ± 0.15
Alogia0.5 ± 0.210.0 ± 0.19
Avolition-Apathy0.2 ± 0.160.1 ± 0.15
Anhedonia-Asociality0.3 ± 0.180.1 ± 0.16
Attention0.4 ± 0.180.3 ± 0.17
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.8771 · Mean difference (final values): 0.0 · 95% CI -0.4 to 0.5
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.0584 · Mean difference (final values): 0.6 · 95% CI 0.0 to 1.1
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.5215 · Mean difference (final values): 0.1 · 95% CI -0.3 to 0.6
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.4835 · Mean difference (final values): 0.2 · 95% CI -0.3 to 0.7
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.5723 · Mean difference (final values): 0.1 · 95% CI -0.4 to 0.7
SecondaryChange From Open-label Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at Week 10 Open-label Phase, LOCF

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Positive and Negative Syndrome Scale (PANSS) Scores at Week 10 Open-label Phase, LOCF
Units on a scaleSPD489 (Open-label Phase)
Positive subscale-1.0 ± 2.23
Negative subscale-4.8 ± 4.01
General Psychopathology subscale-4.0 ± 5.11
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
SecondaryChange From Double-blind Randomization Baseline in PANSS Scores at Week 4 Double-blind Phase, TOCF

The PANSS is a validated measure that evaluates the presence, absence, and severity of 30 symptoms of schizophrenia including both positive and negative symptoms and general psychopathology. Each of the 30-items are rated on a scale of 1 (absent) to 7 (extreme) with a total scoring range of 30 to 210. Higher scores indicate more impairment.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Least squares mean · Units on a scale
Change From Double-blind Randomization Baseline in PANSS Scores at Week 4 Double-blind Phase, TOCF
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Positive subscale0.5 ± 0.31-0.1 ± 0.31
Negative subscale0.9 ± 0.46-0.1 ± 0.45
General Psychopathology subscale0.9 ± 0.78-0.9 ± 0.77
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.1975 · Mean difference (final values): 0.6 · 95% CI -0.3 to 1.5
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.1228 · Mean difference (final values): 1.0 · 95% CI -0.3 to 2.3
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.1115 · Mean difference (final values): 1.8 · 95% CI -0.4 to 3.9
SecondaryPercent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Open-label Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Open-label Baseline
Reported as:
Number · Percent of participants
Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Open-label Baseline
Percent of participantsSPD489 (Open-label Phase)
Normal, not at all ill0
Borderline mentally ill0
Mildly ill29.3
Moderately ill55.4
Markedly ill14.1
Severely ill1.1
Among the most extremely ill0
SecondaryPercent of Participants With CGI-S at Week 10 Open-label Phase

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Week 10 Open-label Phase
Reported as:
Number · Percent of participants
Percent of Participants With CGI-S at Week 10 Open-label Phase
Percent of participantsSPD489 (Open-label Phase)
Normal, not at all ill0
Borderline mentally ill2.9
Mildly ill54.3
Moderately ill38.6
Markedly ill4.3
Severely ill0
Among the most extremely ill0
SecondaryPercent of Participants With CGI-S at Double-blind Randomization Baseline

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Double-blind Randomization Baseline
Reported as:
Number · Percent of participants
Percent of Participants With CGI-S at Double-blind Randomization Baseline
Percent of participantsSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Normal, not at all ill00
Borderline mentally ill2.92.9
Mildly ill50.060.0
Moderately ill38.237.1
Markedly ill8.80
Severely ill00
Among the most extremely ill00
SecondaryPercent of Participants With CGI-S at Week 4 Double-blind Phase

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Week 4 Double-blind Phase
Reported as:
Number · Percent of participants
Percent of Participants With CGI-S at Week 4 Double-blind Phase
Percent of participantsSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Normal, not at all ill00
Borderline mentally ill3.413.8
Mildly ill34.569.0
Moderately ill48.313.8
Markedly ill13.83.4
Severely ill00
Among the most extremely ill00
SecondaryPercent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase

CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Open-label Phase Week 10
Reported as:
Number · Percent of participants
Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase
Percent of participantsSPD489 (Open-label Phase)
Percent of Participants With Improvement on Clinical Global Impression - Change (CGI-C) at Week 10 Open-label Phase30.0
SecondaryPercent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase

CGI-C permits a global evaluation of the change of the subject's overall schizophrenia condition over time. It consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Double-blind Phase Week 4
Reported as:
Number · Percent of participants
Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase
Percent of participantsSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Percent of Participants With Improvement on CGI-C at Week 4 Double-blind Phase17.227.6
SecondaryChange From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase

BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

Time frame:
Open-label Baseline and week 10 Open-label Phase
Reported as:
Mean · correct numerals
Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase
correct numeralsSPD489 (Open-label Phase)
Change From Open-label Baseline in the Brief Assessment of Cognition in Schizophrenia (BACS) Total Score at Week 10 Open-label Phase2.3 ± 8.92
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0307
SecondaryChange From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase

BACS measures attention and speed of processing, and the test score is the total number correct. The measure of the test is the number of correct numerals where subjects write numerals 1-9 as matches to nonmeaningful symbols on a response sheet for 90 seconds, based upon a key provided to them.

Time frame:
Double-blind Randomization Baseline and Week 4
Reported as:
Least squares mean · correct numerals
Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase
correct numeralsSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Double-blind Randomization Baseline in BACS Total Score at Week 4 Double-blind Phase0.1 ± 1.19-2.7 ± 1.21
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.1072 · Mean difference (final values): 2.8 · 95% CI -0.6 to 6.2
SecondaryChange From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase

LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

Time frame:
Open-label Baseline and week 10 Open-label Phase
Reported as:
Mean · correct sequences
Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase
correct sequencesSPD489 (Open-label Phase)
Change From Open-label Baseline in Letter-Number Span Test (LNS) Total Score at Week 10 Open-label Phase0.8 ± 7.72
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.3660
SecondaryChange From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase

LNS is a test of verbal working memory. Subjects are presented with a sequence of numbers and letters aurally and then asked to tell the rater the numbers first from lowest to highest followed by the letters in alphabetical sequence. The measure is the number of correct sequences.

Time frame:
Double-blind Randomization Baseline and Week 4
Reported as:
Least squares mean · correct sequences
Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase
correct sequencesSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Double-blind Randomization Baseline in LNS Total Score at Week 4 Double-blind Phase-0.1 ± 1.261.3 ± 1.28
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.4347 · Mean difference (final values): -1.4 · 95% CI -5.0 to 2.2
SecondaryChange From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase

HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

Time frame:
Open-label Baseline and Week 10
Reported as:
Mean · words recalled
Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase
words recalledSPD489 (Open-label Phase)
Change From Open-label Baseline in Hopkins Verbal Learning Test - Revised (HVLT-R) Total Score at Week 10 Open-label Phase0.7 ± 7.54
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.4312
SecondaryChange From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase

HVLT-R measures verbal learning. Test scores are the total number of words recalled correctly over 3 trials. The test consists of 12 nouns read aloud for 3 consecutive trials and each trial is followed by a recall test.

Time frame:
Double-blind Randomization Baseline and week 4 Double-blind Phase
Reported as:
Least squares mean · words recalled
Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase
words recalledSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Double-blind Randomization Baseline in HVLT-R Total Scores at Week 4 Double-blind Phase-1.5 ± 1.011.0 ± 1.01
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.0874 · Mean difference (final values): -2.5 · 95% CI -5.4 to 0.4
SecondaryChange From Open-label Baseline in University of California Performance-Based Skills Assessment, Brief Version (UPSA-B) Scores at Week 10 Open-label Phase, LOCF

UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

Time frame:
Open-label Baseline and week 10 Open-label Phase
Reported as:
Mean · Scores on a scale
Change From Open-label Baseline in University of California Performance-Based Skills Assessment, Brief Version (UPSA-B) Scores at Week 10 Open-label Phase, LOCF
Scores on a scaleSPD489 (Open-label Phase)
Total Skills6.2 ± 12.20
Communication Skills3.7 ± 8.56
Financial Skills2.5 ± 7.45
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = <0.0001
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0002
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0028
SecondaryChange From Double-blind Randomization Baseline in UPSA-B Scores at Week 4 Double-blind Phase

UPSA-B assesses skills in 5 areas of life functioning. It contains 2 subscales. Percentages correct on these 2 subscales are multiplied by 50. Thus, scores can range from 0 to 50 on each of these 2 subscales, and total scores can range from 0 to 100. Scores of 75 or higher are associated with independent living.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Least squares mean · Scores on a scale
Change From Double-blind Randomization Baseline in UPSA-B Scores at Week 4 Double-blind Phase
Scores on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Total Skills-1.5 ± 1.350.0 ± 1.37
Communication Skills-1.5 ± 1.14-0.6 ± 1.16
Financial Skills-0.3 ± 0.830.9 ± 0.84
Statistical analysis
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.4637 · Mean difference (final values): -1.4 · 95% CI -5.3 to 2.4
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.6137 · Mean difference (final values): -0.8 · 95% CI -4.1 to 2.4
  • SPD489 (Double-blind Phase) vs Placebo (Double-blind Phase) · ANCOVA · p = 0.3482 · Mean difference (final values): -1.1 · 95% CI -3.5 to 1.3
SecondaryChange From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase

BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · T-scores
Change From Open-label Baseline in Behavioral Rating Inventory of Executive Function - Adult Version (BRIEF-A) T-scores at Week 10 Open-label Phase
T-scoresSPD489 (Open-label Phase)
Global Executive Composite-3.9 ± 13.29
Behavioral Recognition Index-3.1 ± 12.89
Metacognition Index-3.9 ± 13.12
Statistical analysis
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0174
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0461
  • SPD489 (Open-label Phase) · t-test, 2 sided · p = 0.0146
SecondaryChange From Double-blind Randomization Baseline in BRIEF-A T-Scores at Week 4 Double-blind Phase

BRIEF-A is a validated 75-item questionnaire composed of three indexes (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Raw scale scores are used to generate T-scores. A reduction in score indicates less impairment.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Least squares mean · T-scores
Change From Double-blind Randomization Baseline in BRIEF-A T-Scores at Week 4 Double-blind Phase
T-scoresSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Global Executive Composite-1.7 ± 1.19-1.2 ± 1.12
Behavioral Recognition Index-0.9 ± 1.22-1.6 ± 1.14
Metacognition Index-2.0 ± 1.26-0.7 ± 1.18
Statistical analysis
  • SPD489 (Double-blind Phase) · ANCOVA · p = 0.7418 · Mean difference (final values): -0.5 · 95% CI -3.8 to 2.7
  • SPD489 (Double-blind Phase) · ANCOVA · p = 0.6429 · Mean difference (final values): 0.8 · 95% CI -2.6 to 4.1
  • SPD489 (Double-blind Phase) · ANCOVA · p = 0.4364 · Mean difference (final values): -1.4 · 95% CI -4.8 to 2.1
SecondaryChange From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Change From Open-label Baseline in Simpson Angus Scale (SAS) Total Score at Week 10 Open-label Phase-0.01 ± 0.063
SecondaryChange From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase

SAS is a 10-item scale used to evaluate the presence and severity of extrapyramidal symptoms. The items are scored on a scale from 0 to 4 with item-specific definitions given for each point. Total scores range from 0 to 40. Lower scores indicate less impairment.

Time frame:
Open-label Baseline and Week 4 Double-blind Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Open-label Baseline in SAS Total Score at Week 4 of Double-blind Phase0.00 ± 0.0930.00 ± 0.043
SecondaryChange From Open-label Baseline in Barnes Akathisia Scale (BAS) Scores at Week 10 Open-label Phase

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Open-label Baseline and week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Barnes Akathisia Scale (BAS) Scores at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Objective0.0 ± 0.17
Subjective0.0 ± 0.56
Global0.0 ± 0.36
SecondaryChange From Open-label Baseline in BAS Scores at Week 4 of Double-blind Phase

BAS scale has objective, subjective, and global impression components of akathisia (motor restlessness that manifests itself with an inability to sit still or remain motionless). Objective and subjective components are rated on a scale from 0 (normal/absence) to 3 (severe) and are summed yielding a total score of 0 to 9. Global impression is rated on a scale from 0 (absent) to 5 (severe) with a total score ranging from 0 to 5. Lower scores indicate reduced restlessness.

Time frame:
Open-label Baseline and Week 4 Double-blind Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in BAS Scores at Week 4 of Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Objective0.0 ± 0.18-0.1 ± 0.24
Subjective0.0 ± 0.31-0.1 ± 0.65
Global0.0 ± 0.18-0.2 ± 0.44
SecondaryChange From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Change From Open-label Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 10 Open-label Phase-1.8 ± 9.69
SecondaryChange From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase

ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.

Time frame:
Double-blind Randomization Baseline and Week 4 Double-blind Phase
Reported as:
Mean · Units on a scale
Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Double-blind Randomization Baseline in ACSA Total Score at Week 4 Double-blind Phase0.4 ± 7.65-2.9 ± 8.75
SecondaryChange From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase

PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Change From Open-label Baseline in Pittsburgh Sleep Quality Index (PSQI) Total Global Score at Week 10 Open-label Phase-0.7 ± 3.15
SecondaryChange From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase

PSQI evaluates 7 areas of quality and pattern of sleep. Each area is rated on a scale from 0 (better) to 3 (worse) with a total score ranging from 0 to 21. Reduction in total scores are associated with better sleep quality.

Time frame:
Open-label Baseline and Week 4 Double-blind Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Open-label Baseline in PSQI Total Global Score at Week 4 of Double-blind Phase0.3 ± 3.01-1.7 ± 3.00
SecondaryChange From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Open-label Baseline and Week 10 Open-label Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase
Units on a scaleSPD489 (Open-label Phase)
Change From Open-label Baseline in Calgary Depression Scale for Schizophrenia (CDSS) at Week 10 Open-label Phase-0.7 ± 2.11
SecondaryChange From Open-label Baseline in CDSS at Week 4 of Double-blind Phase

CDSS is a 9-item scale to evaluate depression in subjects who have schizophrenia rated from 0 (absence of symptoms) to 3 (severe symptoms) with a total score range of 0 to 27. Lower scores indicate less depression.

Time frame:
Open-label Baseline and Week 4 of Double-blind Phase
Reported as:
Mean · Units on a scale
Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase
Units on a scaleSPD489 (Double-blind Phase)Placebo (Double-blind Phase)
Change From Open-label Baseline in CDSS at Week 4 of Double-blind Phase-0.1 ± 2.34-0.7 ± 2.30

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489 (Open-label Phase)—3/92 (3.3%)56/92 (60.9%)
SPD489 (Double-blind Phase)—1/34 (2.9%)11/34 (32.4%)
Placebo (Double-blind Phase)—2/35 (5.7%)7/35 (20%)
Most frequent serious events
Most frequent serious events
EventSPD489 (Open-label Phase)SPD489 (Double-blind Phase)Placebo (Double-blind Phase)
SchizophreniaPsychiatric disorders1/921/341/35
DyspepsiaGastrointestinal disorders0/920/341/35
Chest painGeneral disorders1/920/340/35
HallucinationPsychiatric disorders1/920/340/35
Major depressionPsychiatric disorders1/920/340/35
Most frequent other events
Showing 10 of 41
Most frequent other events
EventSPD489 (Open-label Phase)SPD489 (Double-blind Phase)Placebo (Double-blind Phase)
HeadacheNervous system disorders13/922/342/35
Decreased AppetiteMetabolism and nutrition disorders10/920/340/35
InsomniaPsychiatric disorders10/920/340/35
DizzinessNervous system disorders8/920/340/35
Dry MouthGastrointestinal disorders6/921/340/35
NauseaGastrointestinal disorders2/922/341/35
FatigueGeneral disorders4/922/341/35
DiarrheaGastrointestinal disorders5/920/340/35
VomitingGastrointestinal disorders4/920/340/35
AnxietyPsychiatric disorders4/921/340/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall
Mean42.3 ± 9.11
Age, Customized
Age, Customized(Participants)Overall
<18 years0
Between 18 and 55 years92
>55 years0
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female30
Male62
Region of Enrollment
Region of Enrollment(Participants)Overall
United States92
08

Study locations

27 sites
  • K&S Professional Research Services
    Little Rock, Arkansas 72201, United States
  • South Coast Clinical Trials
    Anaheim, California 92804, United States
  • Omega Clinical Trials
    Anaheim, California 92805, United States
  • Clinical Innovations
    Costa Mesa, California 92626, United States
  • Collaborative Neuroscience Network, Inc.
    Garden Grove, California 92845, United States
  • Apostle Clinical Trials, Inc.
    Long Beach, California 90813, United States
  • Excell Research, Inc.
    Oceanside, California 92056, United States
  • Southcoast Clinical Trials
    San Bernardino, California 92405, United States
  • CNRI San Diego & Los Angeles
    San Diego, California 92102, United States
  • Affiliated Research Institute
    San Diego, California 92108, United States
  • Artemis Institute for Clinical Research
    San Diego, California 92123, United States
  • Neuropsychiatric Research Center of Orange County
    Santa Ana, California 92701, United States
  • Accurate Clinical Trials
    Kissimmee, Florida 34741, United States
  • Behavioral Clinical Research, INC
    Lauderhill, Florida 33319, United States
  • Segal Institute for Clinical Research (Miami)
    North Miami, Florida 33161, United States
  • Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Comprehensive NeuroScience
    Atlanta, Georgia 30328, United States
  • Uptown Research Institute
    Chicago, Illinois 60640, United States
  • J. Gary Booker, MD, APMC
    Shreveport, Louisiana 71104, United States
  • CRI Worldwide, LLC.
    Willingboro, New Jersey 08046, United States
  • Advanced Bio-Behavioral Sciences
    Elmsford, New York 10523, United States
  • Comprehensive Neuroscience, Inc.
    Hollis, New York 11423, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • CRI Worldwide
    Philadelphia, Pennsylvania 19139, United States
  • Community Clinical Research, Inc.
    Austin, Texas 78756, United States
  • University Hills Clinical Research
    Irving, Texas 75062, United States
09

References and documents

Publications

  • Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, Knesevich MA, Lindenmayer JP. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013 Oct;38(11):2140-9. doi: 10.1038/npp.2013.111. Epub 2013 May 8. PubMed 23756608 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2009 to primary completion in Jan 2011, 16 months.

Results were first posted in Feb 2012, 1 year 1 month after primary completion.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 16 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2009
First posted
Jun 17, 2009
StartActual
Sep 14, 2009
Primary completionActual
Jan 20, 2011
CompletionActual
Jan 20, 2011
Results first posted
Feb 20, 2012
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00922272
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jun 17, 2009
Start date
Sep 14, 2009
Primary completion
Jan 20, 2011
Completion
Jan 20, 2011
Results posted
Feb 20, 2012
Last update
Jun 9, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion